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Abstract: The essential features of bipolar affective disorder involve the cyclical occurrence 
of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both 
bipolar I and II disorder are more numerous and last for longer duration than either manic or 
hypomanic episodes. In addition depressive episodes are associated with higher morbidity and 
mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated 
efﬁ  cacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment 
of bipolar depression is less well-studied. The ﬁ  rst treatment approved by the US FDA for 
acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the 
antidepressant ﬂ  uoxetine. Recently, quetiapine monotherapy has demonstrated efﬁ  cacy in the 
treatment of depressive episodes associated with both bipolar I and II disorder and has earned 
US FDA indication for the same.
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Introduction
Bipolar disorder is estimated to affect 3%–7% of population (Angst 1998; Kessler 
et al 2005). Numerous US FDA-approved treatment options exist for the treatment 
of manic phase of bipolar disorder, including lithium, valproic acid and all 5 atypical 
antipsychotics – olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole 
(Gajwani et al 2006).
The burden of bipolar disorder arises mostly from the depressed phase for both 
bipolar I and II disorder. Patients with bipolar I disorder experience depressive symp-
toms for 3 times longer compared with manic periods and report longer recovery times 
for depressed phases compared with manic phases of the illness (Hlastala et al 1997; 
Judd et al 2002). Patients with bipolar II disorder experience even greater duration 
and severity of depressive symptoms as compared to hypomanic mood disturbances 
(Judd et al 2003). Bipolar disorder-related morbidity and mortality can be due to 
suicide attempts and completed suicide. The depressed phase of bipolar disorder is 
associated with an increased risk of suicide compared with the manic phase of the ill-
ness (Leverich et al 2003; Post et al 2003). Bipolar depression is also associated with 
higher impairments in the psychosocial spheres of family, social and occupational 
functioning compared with bipolar mania (Calabrese et al 2004). Even in the absence 
of major depressive episode, subsyndromal depressive symptoms (presence of 2 or 
more depressive symptoms) in bipolar disorder are associated with some disability 
or functional impairment (Altshuler et al 2002). Because of the predominance of 
depressive symptomalogy, the greater time spent in depressive episodes and higher 
frequency of depressive episodes often leads to a misdiagnosis of bipolar disorder 
as major depressive disorder. This can lead to patients receiving inadequate or inap-
propriate treatment such as antidepressant monotherapy. Despite the prevalence and 
impact of depression in bipolar disorder, there are currently only 2 FDA-approved Neuropsychiatric Disease and Treatment 2007:3(6) 848
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agents for its management compared with multiple approved 
agents for management of bipolar mania.
Historically, clinicians have commonly employed combi-
nation pharmacotherapies for bipolar depression, usually an 
antidepressant and a mood stabilizer. Most of the treatment 
guidelines limit the exposure of antidepressants to a few 
months during acute depressive episodes due to concerns 
that it may precipitate treatment emergent mania or cycle 
acceleration. Tricyclic antidepressants and monoamine oxi-
dase inhibitors confer the highest risk for induction of mania 
whereas rates for induction of mania with selective serotonin 
re-uptake inhibitors (SSRIs) are similar to placebo (Goodwin 
and Jamison 1990; Himmelhock et al 1991; Peet 1994).
The purpose of this paper is to review recent evidence in 
support of quetiapine monotherapy for the acute treatment of 
depressive episodes associated with bipolar disorder, as well 
as the data related to safety and tolerability of this atypical 
antipsychotic medication in bipolar depressed patients.
Study design
Quetiapine monotherapy was evaluated for efﬁ  cacy and toler-
ability for patients with BipOlar DEpRession (BOLDER) in 
two separate trials (Calabrese et al 2005; Thase et al 2006). 
Both BOLDER I and II trials were identical in design. A 
double-blind, randomized, ﬁ  xed-dose, placebo-controlled, 
parallel-group monotherapy design was employed for each 
study. BOLDER I was conducted at 39 centers in the US 
between September 2002 and October 2003. BOLDER II 
was conducted at 41 centers in the US between June 2004 
and August 2005. There were 21 centers in common between 
the two trials. Compared with prescription of quetiapine in 
bipolar mania trials where patients were hospitalized and 
received quetiapine twice a day, the BOLDER trials enrolled 
outpatients and quetiapine was administered in once-a-day 
dosing (Gajwani et al 2006). These trials were designed to 
examine efﬁ  cacy of 2 ﬁ  xed doses of quetiapine, 300 mg and 
600 mg per day, compared with placebo, in patients with 
moderate to severe bipolar depression. The structured clinical 
interview for Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV) was used to conﬁ  rm 
diagnosis. Prior to study initiation, all raters were trained and 
certiﬁ  ed. As much as possible, each patient’s rating was to be 
performed by the same rater using throughout the study.
Inclusion criteria allowed outpatients (aged 18–65 years) 
who met DSM IV criteria for bipolar I or II disorder and 
were experiencing a major depressive episode. Patients with 
rapid-cycling bipolar disorder were also included. Patients 
were required to have Hamilton Depression Rating Scale 
(Hamilton 1960) (HAM-D) 17-item score 20, a Hamilton 
Depression Scale item 1 score 2 and Young Mania Rating 
Scale (Young et al 1978) score 12 at both screening and 
randomization. To minimize potential rating inﬂ  ation of the 
screening and randomization scores, inclusion criteria were 
based on initial HAM-D score while the primary efﬁ  cacy 
measure during the study was based on Montgomery-Åsberg 
Depression Rating Scale scores (MADRS) (Montgomery 
and Åsberg 1979). The primary efficacy variable was 
the change in MADRS total score from baseline to week 8. 
The following secondary outcomes were also measured: the 
proportion of patients achieving response (50% reduction 
in MADRS score from baseline), the proportion of patients 
who achieved remission (MADRS 12) and analysis of 
individual MADRS items.
Exclusion criteria included (1) diagnosis of an Axis I 
disorder other than bipolar disorder that was the primary 
focus of treatment within last 6 months, (2) a current episode 
of depression that had lasted more than 12 months or less 
than 4 weeks in duration, (3) failure to respond to 2 adequate 
(6 weeks) trial of more than 2 classes of antidepressants 
during the current episode, and (4) a current (within last 12 
months of screening) diagnosis of substance dependence or 
abuse (except nicotine). Patients with signiﬁ  cant medical ill-
nesses or patients who currently posed serious risk of suicide 
or homicide were also excluded.
After obtaining written informed consent, patients 
were randomly assigned to either of the three treatment 
arms – quetiapine 300 mg, quetiapine 600 mg or placebo 
(Table 1). Random assignment was stratiﬁ  ed according to 
bipolar type (I or II) to ensure 2:1 ratio for bipolar diagnosis. 
Lorazepam (1–3 mg/day) and zolpidem tartarate (5–10 mg 
at bedtime) were permitted during the ﬁ  rst 3 weeks of ran-
domization but were withheld for 8 hours prior to psychiatric 
assessment. Enrolled patients underwent a washout period for 
7–28 days wherein any prior medications were tapered off 
and were then treated for 8 weeks in double-blinded fashion. 
Quetiapine was initiated at 50 mg/day and titrated to achieve 
300 mg/day by day 4 or 600 mg/day by day 7.
Results
During the BOLDER I trial, a total of 838 patients were 
screened and 542 patients with bipolar I (n = 360) or II 
(n = 182) were randomly assigned to receive quetiapine 
600 mg/day (n = 180), quetiapine 300 mg/day (n = 181), 
or placebo (n = 180). Of the randomized patients, 511 
received at least one post baseline assessment and were 
analyzed for efﬁ  cacy in the intent to treat analysis. There Neuropsychiatric Disease and Treatment 2007:3(6) 849
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were no signiﬁ  cant differences in baseline characteristics. 
The mean age was approximately 37 years and 58.2% of 
the patients were women. Patients’ baseline MADRS scale 
scores reﬂ  ected moderate to severe depression (∼30) (Muller 
et al 2003). The proportion of patients completing the study 
was 54% in the quetiapine 600 mg/day group, 67% in the 
quetiapine 300 mg/day group and 59% in the placebo group. 
The most common reason for withdrawal from the study 
was adverse events in the quetiapine group (26.1% for 600 
mg/day and 16% for 300 mg/day) and lack of efﬁ  cacy in the 
placebo group (13.3%).
Quetiapine at a daily dose of either 300 mg or 600 mg 
demonstrated signiﬁ  cant improvement in the MADRS total 
scale scores as early as week 1 and at all times thereafter. 
The mean change in the MADRS scale scores from base-
line to last assessment was –16.73 in the quetiapine 600 
mg/day group, –16.39 in the quetiapine 300 mg/day group 
compared –10.26 in the placebo group. At ﬁ  nal assessment, 
approximately 58% patients met response criteria in the 
quetiapine groups compared with 36.1% in the placebo 
group. Remission criteria were met by 52.9% of patients 
in both quetiapine groups compared with placebo group’s 
28.4%. On individual MADRS item factor analysis, 9 out 
of 10 depression scale items were signiﬁ  cantly improved 
in the quetiapine 600 mg/day group and 8 out of 10 in the 
quetiapine 300 mg/day group. Both doses of quetiapine were 
more effective than placebo in reducing suicidal thoughts 
at ﬁ  nal assessment. Statistically superior improvement was 
seen from baseline in MADRS total score irrespective of the 
type of illness (bipolar I or II) or presence of rapid cycling 
compared with placebo. Quetiapine-treated patients also 
demonstrated statistically signiﬁ  cant improvement on the 
Clinical Global Impression (CGI) improvement scale (much 
or very much improved was 55.9% for the quetiapine 600 
mg/day group, 64% for the quetiapine 300 mg/day group 
compared with 34.3% on placebo.
In the BOLDER II trial, a total of 788 patients were 
screened and 509 patients with bipolar I (n = 338) or bipo-
lar II (n = 171) disorder were randomly assigned to receive 
quetiapine 600 mg/day (n = 169), quetiapine 300 mg/day 
(n = 172) or placebo (n = 168). Of the randomized patients, 
467 received at least one post-baseline assessment and were 
analyzed for efﬁ  cacy in the intent-to-treat analysis. There 
were no signiﬁ  cant differences in baseline characteristics. 
The mean age was approximately 37 years and 57% of 
the patients were women. Patients baseline MADRS scale 
scores reﬂ  ected moderate to severe depression (ranged from 
29.6–31.1) (Muller et al 2003). The proportion of patients 
completing the study was 53.3% in the quetiapine 600 mg/
day group, 58.7% in the quetiapine 300 mg/day group and 
Table 1 Comparing the BOLDER studies
    BOLDER I        BOLDER II    
  Placebo  Seroquel-300 Seroquel-600 Placebo  Seroquel-300 Seroquel-600
N  181  181 180 168  172 169
DSM-IV  diagnosis         
BP 1 (%)  66.3  67.4  67.1  68.3  67.1  66.9
BP II (%)  33.7  32.6  32.9  31.7  32.9  33.1
RCBD  20.7  24.4 18.2 32.9  28.4 30.5
mean  age  38.3  36.6 37.3 37.7  37.2 38.2
sex  (%)         
male  37.9  45.9 41.8 39.8  44.5 45
female  62.1  54.1 58.2 60.2  55.5 55
baseline  scores         
MADRS  30.6  30.4 30.3 29.6  31.1 29.9
HAM-D  24.6  24.5 24.7 24.3  24.9 24.3
CGI  4.4  4.4 4.5 4.5  4.6 4.4
Mean change in score           
MADRS  −10.26  −16.39  −16.73  −11.93  −16.94  −16
HAM-D  −8.54  −13.38  −13.84  −9.92  −13.81  −12.97
CGI  2.97  2.27 2.37 2.88  2.28 2.29
Response  rates  36.10%  58% 58% 44.70%  60.00%  58.30%
Remission  rates  28.40%  52.90% 52.90% 37.30%  51.60% 52.30%
Effect size in BP I    0.91  1.09    0.67  0.51
Effect size in BP II    0.28  0.39    0.56  0.64
Abbreviations: BP, bipolar; CGI, Clinical Global Impression; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; HAM-D, Hamilton depression 
rating scale; MADRS, Montgomery-Åsberg Depression Rating Scale scores; RCBD, rapid cycling bipolar disorder.Neuropsychiatric Disease and Treatment 2007:3(6) 850
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65.5% in the placebo group. The most common reason for 
withdrawal in the quetiapine-treatment groups was adverse 
events versus lack of efﬁ  cacy in the placebo group.
Quetiapine at either dose led to signiﬁ  cantly greater 
improvement in MADRS total score at week 1 and at 
all times thereafter compared with placebo. The mean 
change in the MADRS scale scores from baseline to last 
assessment was –16.00 in the quetiapine 600 mg/day group 
and –16.94 in the quetiapine 300 mg/day group compared 
with –11.93 in the placebo group. At ﬁ  nal assessment, 
approximately 58.3%–60% patients met response criteria in 
the quetiapine groups compared with 44.7% in the placebo 
group. Remission criteria were met by 51.6%–52.3% of 
patients in both quetiapine groups compared the placebo 
group’s 37.3%. On MADRS item analysis in this study, the 
majority of individual depression scale items signiﬁ  cantly 
improved with both 300 mg and 600 mg quetiapine treat-
ment. Both doses of quetiapine were more effective than 
placebo in reducing suicidal thoughts at ﬁ  nal assessment. 
Statistically superior improvement was seen from baseline 
in MADRS total score irrespective of the type of illness 
(bipolar I or II) or presence of rapid cycling as compared 
to placebo. Quetiapine-treated patients also demonstrated 
statistically signiﬁ  cant improvement on the CGI severity 
and improvement scale (“much improved” or “very much 
improved” was reported in 60% of the quetiapine 600 
mg/day group, 61.3% of the quetiapine 300 mg/day group 
and only 38.5% of the placebo).
BOLDER I reported the effect size in bipolar I depres-
sion to be 1.09 for those patients assigned to the 600 mg/day 
group and 0.91 for those taking 300 mg/day of quetiapine. 
The effect size in the bipolar II subgroup was 0.39 in the 600 
mg/day group and 0.28 in the 300 mg/day group. BOLDER 
II reported effect size in bipolar I subgroup to be 0.51 for the 
600 mg/day group and 0.67 for the 300 mg/day group. The 
reported effect size in the bipolar II subgroup was 0.64 for 
patients receiving 600 mg/day and 0.56 for patients receiving 
300 mg/day of quetiapine.
Safety and tolerability
During the BOLDER I trial, 2 patients attempted suicide, one 
in each of the quetiapine groups, but no suicides or deaths 
occurred during the study. The overall rate of study discon-
tinuation due to adverse events was 26.1% (n = 47) in the 
600 mg/day group, 16.0% (n = 29) in the 300 mg/day group 
and 8.8% (n = 16) in the placebo group. The incidence of 
treatment-emergent mania was low in the quetiapine groups 
compared with placebo (2.2% with 600 mg/day, 3.9% with 
300 mg/day and 3.9 % with placebo). Extrapyramidal adverse 
events were present in 8.9% of the 600 mg/day group, 6.7% 
of the 300 mg/day group and 2.2 % of the placebo group. 
The rate of discontinuation in the quetiapine group due to 
extrapyramidal symptoms was low (1.1%–2.8%). Reported 
weight gain was as follows: 0.2 kg in the placebo group, 
1.0 kg in the 300 mg/day group, 1.6 kg in the 600 mg/day 
group. Signiﬁ  cant weight gain as deﬁ  ned by weight gain of 
7% from baseline was reported in 1.7% in the placebo 
group, 8.5% in the 300 mg/day group and 9.0% in the 600 
mg/day group.
During the BOLDER II study, no deaths occurred. The 
overall rate of study discontinuation due to adverse events 
was 11.2% (n = 19) in the 600 mg/day group, 8.1% (n = 14) 
in the 300 mg/day group and 1.2% (n = 2) in the placebo 
group. The incidence of treatment-emergent mania was 
higher in the placebo group than in either of the quetiapine 
groups (3.6% with 600 mg/day, 1.8% with 300 mg/day and 
6.6% with placebo). Extrapyramidal adverse events were 
present in 10.1% of the 600 mg/day group, 12.3% of the 300 
mg/day group and 6.6 % of the placebo group. The rate of 
discontinuation in the quetiapine group due to extrapyramidal 
symptoms was low (0.6% in the 600 mg/day group). Reported 
weight gain was as follows: 0.3 kg in the placebo group, 1.4 
kg in the 300 mg/day group, 1.3 kg in the 600 mg/day group. 
Signiﬁ  cant weight gain as deﬁ  ned by weight gain of 7% 
from baseline was reported in 2.8% in placebo group, 3.9% 
in the 300 mg/day group and 8.6% in the 600 mg/day group. 
There was no signiﬁ  cant change in the fasting blood glucose 
level from baseline to ﬁ  nal assessment.
During both BOLDER I and II trials, no patient with-
drew from the study due to weight gain. There was no 
signiﬁ  cant change in the fasting blood glucose level from 
baseline to ﬁ  nal assessment with quetiapine or placebo 
treatment and the mean fasting glucose level for all groups 
remained within the normal range. Also, no clinically 
important differences between groups were reported in 
both BOLDER studies in the mean change from baseline 
for any vital signs, electrocardiograms, hematology, or 
clinical chemistry parameters.
Discussion
The BOLDER studies were large scale, multi-center, random-
ized, placebo-controlled trials that examined the efﬁ  cacy of 
quetiapine monotherapy in acute bipolar depression. These 
were the ﬁ  rst large-scale, controlled studies published to 
date that enrolled patients with both bipolar I and II disorder 
and included patients with rapid cycling bipolar disorder. Neuropsychiatric Disease and Treatment 2007:3(6) 851
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Based on the results, quetiapine has demonstrated signiﬁ  cant 
antidepressant efﬁ  cacy in the depressed phase of bipolar 
disorder. Based on the primary efﬁ  cacy scale (MADRS), 
improvement was evident from week 1 and maintained for 
the duration of the study (8 weeks). In the MADRS item 
analysis, both doses of quetiapine produced a signiﬁ  cant 
and sustained improvement in most of the core symptoms 
of mood including decrease in suicidal thinking. Similarly, 
significant improvement was observed in patients with 
bipolar I and II disorder and in patients with or without rapid 
cycling. The therapeutic beneﬁ  t of quetiapine 300 mg/day 
and 600 mg/day was similar at study end point. The FDA has 
approved the quetiapine 300 mg/day dose in the treatment 
of bipolar depression.
The rate of quetiapine induced treatment-emergent mania 
was low, 2%–4%, and on par with the 4%–7% rate observed 
with placebo. It can be concluded that antidepressant efﬁ  cacy 
of quetiapine was not at the expense of treatment-emergent 
affective switches. A low risk of treatment-emergent affec-
tive switches may be one of the strongest advantages offered 
in the management of bipolar depression. However, it must 
be noted that in a short treatment trial such as these 8-week 
depression studies, this placebo-level switch rate applies 
only to that brief period studied and cannot exclude the 
possibility of switches later during the course of ongoing 
treatment. This seems less likely with an agent such as que-
tiapine which is also known to be and is an approved as an 
antimanic agent.
Reported side effects were similar in both trials. Most 
commonly reported side effects included dry mouth, seda-
tion, somnolence, dizziness and constipation. Sedation and 
somnolence were the commonest cited reason for withdrawal 
from the study, with most discontinuation occurring in ﬁ  rst 
week. Higher drop out rates were observed in the quetiap-
ine 600 mg/day arm compared with quetiapine 300 mg/day 
arm. Weight gain was 1.2 kg in the quetiapine 300 mg arm 
and 1.5 kg in the quetiapine 600 mg arm, and no patients 
withdrew from study due to weight gain. A small increase in 
fasting plasma glucose level was observed in the quetiapine 
and placebo arms and no patients developed diabetes. The 
mean change in Simpson Angus Scale (SAS) and Barnes 
Akathisia Rating Scale (BARS) was low and generally 
comparable across the three arms.
Comparing the two studies overall, higher placebo 
response rates were seen in the BOLDER II trial which 
resulted in net lower magnitude of response rates for que-
tiapine versus placebo. The change from baseline MADRS 
was comparable in both quetiapine groups in both BOLDER 
I and II trials. It is possible that physician and patient bias 
could have artiﬁ  cially elevated the placebo response rates 
in BOLDER II trial, as results from BOLDER I study were 
published and widely known at the time the BOLDER II trial 
was being conducted. BOLDER II compared with BOLDER 
I demonstrated signiﬁ  cant improvement in the bipolar II 
subpopulation. Comparable efﬁ  cacy was observed in the 
subpopulation of patients with rapid-cycling bipolar disorder 
compared with non-rapid-cycling bipolar disorder.
Limitations of these studies include lack of data on doses 
other than 300 mg/day or 600 mg/day of quetiapine in bipolar 
depression. Also it is difﬁ  cult to comment on efﬁ  cacy of the 
600 mg/day dose for patients failing to respond to quetiapine 
300 mg/day. It is also unknown if patients not responding to 
quetiapine 600 mg/day would beneﬁ  t from any further dose 
titration. Patients at higher risk of suicide were excluded 
from the study which limits the conclusion of data to acutely 
suicidal bipolar depressed patients. Patients with current 
alcohol or illicit drug dependence were excluded, hence 
no conclusion can be drawn about efﬁ  cacy of quetiapine in 
dual-diagnosis bipolar disorder.
In a similar double-blind, placebo-controlled, 8-week-long 
trial, 833 adults with bipolar depression (MADRS score of 
at least 20) were randomized to receive placebo (n = 377); 
olanzapine, 5–20 mg/day (n = 370); or olanzapine-ﬂ  uoxetine 
combinations, 6 and 25, 6 and 50, or 12 and 50 mg/day (n = 86) 
(Tohen et al 2003). Mean modal drug dose for olanzapine 
monotherapy was 9.7 mg/day and 7.4 mg/day of olanzapine 
with 39.3 mg/day of ﬂ  uoxetine for olanzapine-ﬂ  uoxetine 
arm. At week 8, MADRS scores were lower than baseline 
by 11.9, 15.0 and 18.5 points in the placebo, olanzapine and 
olanzapine-ﬂ  uoxetine groups respectively. The therapeutic 
effect size was 0.32 for olanzapine and 0.68 for olanzapine-
ﬂ  uoxetine combination. The response rates were 30.4% for 
placebo, 39% for olanzapine monotherapy and 56.1% for 
olanzapine-ﬂ  uoxetine combination. Olanzapine-ﬂ  uoxetine 
was found to be more effective than olanzapine monotherapy 
and placebo in the treatment of bipolar depression.
The mechanism of action by which quetiapine can effec-
tively treat bipolar depression is unknown. This antipsychotic 
and antimanic agent, now with reported antidepressant 
effects, is an antagonist at multiple neurotransmitter recep-
tor sites in the brain, including 5HT1A, 5HT2, D1, D2, 
histamine H1, alpha-1 and alpha-2. Its dopamine antago-
nism may be responsible for its antipsychotic and antimanic 
effects. Quetiapine is metabolized by 4 routes, including 
hydroxylation, sulfoxidation, oxidation and dealkylation. 
Dealkylation generates the primary active metabolite of Neuropsychiatric Disease and Treatment 2007:3(6) 852
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the parent compound, nor-quetiapine. Nor-quetiapine has 
high afﬁ  nity and is a potent inhibitor of the noradrenergic 
transporter (Ki = 35 nM), and has partial agonistic activity 
at the serotonin 5HT1A receptor (Goldstein et al 2007). 
These findings suggest that quetiapine interacts with 3 
principal neuro-transmitter involved in regulation of mood: 
norepinephrine, serotonin and dopamine. It is likely that 
these broader neurotransmitter effects, confer antidepressant 
properties to quetiapine.
Management of bipolar depression is one of the most 
challenging tasks faced by clinicians and represents one of 
the greatest unmet needs for our patients. Antidepressants 
are frequently used with mood stabilizers for treatment of 
bipolar depression, despite limited evidence and concerns 
about potential increased risk of change in mood polarity 
(Goodwin and Jamison 1990; Leverich et al 2006). In a 
recently published study (Sachs et al 2007), effectiveness 
of antidepressants with mood stabilizers was compared with 
placebo with mood stabilizers. The study was conducted 
by the Systematic Treatment Enhancement Program for 
Bipolar Disorder (STEP-BD), a collaboration sponsored 
by the National Institute of Mental Health designed to 
evaluate the effectiveness of treatments for bipolar disorder. 
366 patients were enrolled in this 26-week trial which 
included paroxetine up to 40 mg/day, bupropion extended 
release up to 375 mg/day added to lithium, valproate, 
carbamazepine or one of the approved antimanic agents. 
The results demonstrated that the use of antidepressant 
medication versus placebo adjunctive to mood stabilizers 
conferred no beneﬁ  t. In addition the rates of treatment-
emergent affective switch were similar in the antidepres-
sant group and placebo. Although this study utilized only 
paroxetine and bupropion, which limits the generalizability 
to all other classes of antidepressants, it is the ﬁ  rst large-
scale study designed to assess effectives of commonly 
employed antidepressants (paroxetine and bupropion) in 
the management of bipolar depression. Further long-term, 
head-to-head comparison studies are needed fully assess 
the role of antidepressants versus atypical antipsychotics 
in the management of bipolar depression.
Conclusion
At this stage, quetiapine appears to be the antipsychotic agent 
for which the evidence is strongest to support its use in the 
treatment of bipolar depression. When ﬁ  rst published, initial 
ﬁ  ndings from BOLDER I led clinicians to believe that the 
magnitude of antidepressant efﬁ  cacy with quetiapine was 
large, though the conﬁ  rmatory BOLDER II trial indicates that 
quetiapine’s effects are likely to be only moderate. A post-hoc 
analysis (Cookson et al 2007) was recently published on 
BOLDER I data which suggested that when translated into 
clinically meaningful terms, the data indicate that between 
4 and 9 patients would have to be treated with quetiapine 
in order for one additional patient to achieve a response 
beyond what would be produced by placebo. This illustrates 
the unmet need that still exists for effective and tolerable 
antidepressant agents in the management of bipolar depres-
sion. Given that quetiapine exerts both acute antidepressant 
and antimanic activity in monotherapy, it may be considered 
the atypical antipsychotic most representative of a “mood 
stabilizer”. A shortcoming when considering the spectrum 
of quetiapine studies is the lack of maintenance phase data. 
Such studies would address whether antidepressant effects 
are maintained beyond the acute assessment period and 
address quetiapine’s role in prevention of recurrence of new 
mood episodes, particularly new episodes of depression. 
Given the rather low response and remission rates with any 
agent in bipolar depression and the propensity for relapse, 
newer therapies continue to be needed to bring relief from 
this most complex illness.
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